RGZ treatment was associated with a significant increase in CXCL12 and a decrease in CXCR4 and CXCR7 expression only in the primary tumor H295R cell line (Figure 4C), while no significant effects were observed in the metastatic MUC-1 cell line (Figure 4D). Here, CXCL12 is linked to neoplasm.